TO THE EDITOR,
==============

We read the publication entitled "Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation" with great interest \[[@ref1]\]. As summarized by Atilla et al. \[[@ref1]\], "Organ dysfunction due to iron overload may cause high mortality rates and therefore a sufficient iron chelation therapy is recommended". We would like to share the experience from our settings where there is a very high prevalence of thalassemia and transplantation is the only curative treatment.

Iron overload is common among transfusion-dependent thalassemia patients and transfusion during transplantation might increase the risk of the complication of iron overload. However, in clinical practice, the problem is not common and improvement of the patients after transplantation is reported. According to the recent report by Inati et al. \[[@ref2]\], with standard chelation therapy, the outcome of thalassemic patients undergoing stem cell transplantation is usually favorable. The use of the standard dosage of deferoxamine, with or without phlebotomy, accompanied with close iron status monitoring can be effective \[[@ref2],[@ref3]\]. It can be seen that stem cell transplantation can be problematic despite there being a need of hypertransfusion during the process even though the patient might have an underlying severe iron overload condition such as thalassemia.

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

Authors\' Response

Atilla

Erden

Toprak

Selami K.

Demirer

Taner

Dear Sora Yasri,

Thank you very much for your valuable comments and sharing your experience. We agree for your contribution. In thalassemia patients, several transplantation centers categorised risk factors prior to allogenic hematopoietic stem cell transplantation. Pesaro classification assigned patients to three arms according to the absence or presence of one, two or three risk factors: hepatomegaly \> 2 cm, portal fibrosis, and irregular chelation history \[[@ref1-1]\]. It should be kept in mind that in a study by Ghavamzadeh et al., liver iron overload did not change after transplant (p=0.61) but hepatic fibrosis progressed (p=0.01) \[[@ref1-2]\]. Allogeneic stem cell transplantation did not reduce liver iron overload and in fact liver fibrosis increased. Also steps for reducing iron overload should be taken in the post transplant setting \[[@ref1-3]\]. Iron overload is still an essential issue in both pre and post transplant settings. Survival in transfusion-dependent thalassemia patients can be improved with proper understanding of the pathophysiology of thalassemia and iron toxicity.

Regards,
